Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

As Eli Lilly looks to hold its lead in the lucrative obesity market, the company’s next-gen prospect, the triple-G drug retatrutide, has met the primary endpoint for weight loss in another pivotal study. Though the results show competitive efficacy and tolerability, they may leave some observers sli